Evidence map›Paper›PMID 39392602›Full record

ArticleJournal of Alzheimer's disease : JAD2024

The Association Between Plasma Amyloid-β 42/40 and Percentage of Semantic Intrusion Errors in Mild Cognitive Impairment.

Rosie E Curiel Cid, Alexandra Ortega, David Vaillancourt, Breton Asken, Elizabeth A Crocco, Melissa J Armstrong, Ranjan Duara, Kirsten Crenshaw, Malek Adjouadi, Monica Rosselli and 2 more

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The importance of cognitive correlates of plasma amyloid-β 42/40.Journal of Alzheimer's disease : JAD · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rosie E Curiel Cid1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
Alexandra Ortega1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
David Vaillancourt1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
Breton Asken1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
Elizabeth A Crocco1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
Melissa J Armstrong1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
Ranjan Duara1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
Kirsten CrenshawCenter for Cognitive Neuroscience and Aging (CNSA), Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Malek Adjouadi1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
Monica Rosselli1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
Wei-En Wang1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.
David A Loewenstein1Florida Alzheimer's Disease Research Center (ADRC), Miami, FL, USA.

Funding

Social Determinants of Health, Race/Ethnicity, and White Matter HyperintensitiesP30AG066506 · NIA · UNIVERSITY OF FLORIDA · PI Ranjan Duara, DAVID LOEWENSTEIN · 2020 to 2026
$25.6M
A Novel Computerized Cognitive Stress Test Designed for Clinical Trials in Early Alzheimer's: Relationship with Multimodal Imaging Biomarkers in Diverse Cultural GroupsR01AG061106 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOEWENSTEIN, DAVID · 2019 to 2023
$3.6M
Novel Detection of Early Cognitive and Functional Impairment in the ElderlyR01AG047649 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOEWENSTEIN, DAVID · 2015 to 2019
$2.7M
NIA NIH HHS P30 AG066506NIA NIH HHS R01 AG047649NIA NIH HHS R01 AG061106
6 · The paper itself

Abstract

Background: Semantic intrusion errors (SIEs) are both sensitive and specific to PET amyloid-β (Aβ) burden in older adults with amnestic mild cognitive impairment (aMCI). Objective: Plasma Aβ biomarkers including the Aβ42/40 ratio using mass spectrometry are expected to become increasingly valuable in clinical settings. Plasma biomarkers are more clinically informative if linked to cognitive deficits that are salient to Alzheimer's disease (AD). Methods: This study included 119 older adults enrolled in the 1Florida Alzheimer's Disease Research Center (ADRC), 45 aMCI participants scored below the established Aβ42/40 ratio cut-off of 0.160 using the Quest AD-Detect™ assay indicating Aβ positivity (Aβ+), while 50 aMCI participants scored above this cut-off indicating Aβ negative status (Aβ-). Additionally, 24 cognitively unimpaired (CU) persons scored above the cut-off of 0.160 (Aβ-). Results: The aMCI plasma Aβ+ group evidenced the greatest percentage of SIEs, followed by the aMCI Aβ-. The CU Aβ- group exhibited the lowest percentage of SIEs. After adjustment for global cognitive impairment, aMCI plasma Aβ+ continued to demonstrate greater SIEs on tests tapping the failure to recover from proactive semantic interference (frPSI) as compared to the aMCI Aβ-group. Using pre-established cut-offs for frPSI impairment, 8.3% of CU Aβ- participants evidenced deficits, compared to 37.8% of aMCI Aβ-, and 74.0% of aMCI Aβ+. Conclusions: SIEs reflecting frPSI were associated with aMCI Aβ+ status based on the Aβ42/40 ratio. Results suggest the importance of SIEs as salient cognitive markers that map onto underlying AD pathology in the blood.

Indexed as

Amyloid beta-PeptidesBiomarkersCognitive DysfunctionPeptide FragmentsSemanticsAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeuropsychological TestsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersPeptide FragmentsAlzheimer’s diseaseamyloid-βAβ42/40LASSI-Lmild cognitive impairmentplasma biomarkerssemantic intrusion errors

Identifiers

PMID39392602
PMCPMC12097436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.